Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation

about

Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation

Item

http://www.wikidata.org/entity/Q37217235

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Benefits of Early Roflumilast ...... charge for a COPD Exacerbation

@en

Benefits of Early Roflumilast ...... harge for a COPD Exacerbation.

@nl

type

Item

label

Benefits of Early Roflumilast ...... charge for a COPD Exacerbation

@en

Benefits of Early Roflumilast ...... harge for a COPD Exacerbation.

@nl

prefLabel

Benefits of Early Roflumilast ...... charge for a COPD Exacerbation

@en

Benefits of Early Roflumilast ...... harge for a COPD Exacerbation.

@nl

P1476

Benefits of Early Roflumilast ...... charge for a COPD Exacerbation

@en

P2093

Michelle Mocarski

http://www.w3.org/2001/XMLSchema#string

Qing Lee

http://www.w3.org/2001/XMLSchema#string

Shawn X Sun

http://www.w3.org/2001/XMLSchema#string

P2860

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data.

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.

Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives.

Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.

Development and validation of a claims-based prediction model for COPD severity.

Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020.

Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease.

Deaths: leading causes for 2010.

P304

140-150

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27606039

http://www.w3.org/2001/XMLSchema#string

P932

5004810

http://www.w3.org/2001/XMLSchema#string